When it comes to interfaces, storage, outcomes reporting, and HIPAA compliance, molecular lab personnel might need to demand more from their LIS vendors, researchers said.
OpGen will provide genetic panels and analysis software to the DOH's Wadsworth Center while Merck's Ilúm will provide health data aggregation and insights.
The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.
The framework, called HEAL, could be used as an early screening test for AAA and as a personal health management tool. In addition, it may be applicable to other complex diseases.
The system relies on the use of scannable safety code cards containing patient data, along with a web portal and automated analysis tools that deliver customized diagnostic reports.
The company’s software-as-a-service and sequencing and molecular analysis revenues grew, and the firm narrowed its loss from a year ago.
NewStem is developing a technology that uses human haploid embryonic stem cells to predict cancer drug resistance.
As Dana-Farber migrates its dozens of medical and radiation oncology protocols to the Philips platform, its focus is on digital pathology, genomics, and informatics.
Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.
Inspirata plans to leverage Caradigm's software to accelerate the development of Inspirata's cancer big data platform called Cancer Information Data Trust.
The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
The companies will jointly offer pathology and molecular testing services to PPD's pharmaceutical and biotechnology customers.
The companies will pair Freenome's AI genomics platform with various Qiagen molecular analysis platforms and co-market the technologies to pharmaceutical companies.
The partners will develop and implement bioinformatics tools, pipelines, and techniques to improve molecular profiling for research and clinical oncology.
Malaysia-based ScienceVision has agreed to commercialize and distribute the PierianDx Clinical Genomics Workspace platform in Southeast Asian countries.
The company said 677 of its GPS Cancer commercial tests were ordered in Q1 2018, up from 606 in Q4 2017.
Helomics' managing executives will remain to manage TumorGenesis, Precision's newly formed subsidiary for cancer diagnostics and therapy.
The firms will work to accelerate the adoption of PierianDx's genomics platform for translating data into patient-specific diagnoses and treatments.
Only three out of 10 sequencing workflows detected all variants in a synthetic reference sample, according to a study presented at ACMG.
The firm said it will use the funding to consolidate its position in clinical diagnostics, establish a US office, and enter new diagnostic markets.